Best Life Sciences Platforms and Tools Companies in Massachusetts, United States

Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases. The company is focused on targeting the biology of aging, which is the biggest risk factor for most chronic diseases. They are developing a novel partial epigenetic reprogramming platform that targets a key underlying mechanism of aging to prevent and reverse age-related diseases with significant unmet need to extend healthy human lifespan. This approach holds the promise of treating many of the most debilitating and chronic diseases. The platform builds on innovative science from world-leading researchers to partially reprogram the epigenome of aged and injured cells to restore cellular function to a younger state. This is a B2B model.

Developer of in vitro models for drug development. The company has culture modules, organ-chips, and analytical software applications. The proprietary Organ-Chip models including the liver, intestine, kidney, and others contain tiny hollow channels lined with tens of thousands of living human cells and tissues are designed to predict human response.

Developer of transformational medicines for neurological disorders. The company combines advanced human cellular models, unique measurement engineering, artificial intelligence, and machine learning into a proprietary platform to discover new drugs for neurological disease. The company's lead candidate is UBE3A for Seizure and Neurodevelopment Disorders.

Funding rounds

• Apr 2026Series B—
• Dec 2025Grant (prize money)$3M
• Jul 2025Grant (prize money)$2.1M
• Mar 2025Grant (prize money)$2.2M

Founders & team

Paul RomaCo-FounderGraham DempseyCo-FounderDavid MarguliesCo-Founder and Chairman

Investors

NIH, HHS

Dewpoint Therapeutics is involved in development of small molecules based therapeutics. The company offers condensate biology to create dynamic, liquid compartments in cells for the treatment of neurodegeneration, cancer, and other diseases.

Funding rounds

• Sep 2025Series D$59.1M
• Feb 2022Series C$150M
• Sep 2020Series B$77.1M
• Jan 2019Series A$60M

Founders & team

Richard YoungCo-FounderAmeet NathwaniChief Executive Officer

Investors

Polaris Partners, Samsara BioCapital, 6 Dimensions Capital, EcoR1, Alexandria, Leaps by Bayer

iSpecimen is a supplier of human clinical specimens to the therapeutic, diagnostic, and academic research industries. The platform supply researchers with a range of liquid and solid specimens such as plasma, serum, whole blood, urine, CSF, and FFPE blocks and slides. Their customers include researchers in contract research organizations, government agencies, and academic institutions.

Manufacturer of system for early disease detection and prognosis

Redshift uses microfluidics modulation systems along with a tunable laser to develop analytical instruments for the detection of the very low level of analytes in the fluid. The technology can be applied in protein therapeutics detection where measurement of low concentration of the protein is critical. The instrument called ProLaser is used for lead candidate selection, preformulation and formulation development, process development optimization, and measuring and predicting stability, as well as for routine analytics, process monitoring, and QC release.

Funding rounds

• Jun 2025Series E$5.9M
• Mar 2024Series E$5M
• Oct 2021Series E$20M
• Dec 2020Series D$6.4M

Founders & team

Eugene MaCo-founder & CTO

Investors

Technology Venture Partners, Waters Corporation, Alta Partners, Emerson, InterWest Partners, Vesbridge Partners

Tech stack

CdnjsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCloudflare TurnstileCookie Script

Developer of technologies to store blood and its products. They have developed 2 distinctive technologies namely Hemanext and MicroVascular Analyzer (measures RBC deformability). Hemanext enables the storage of RBC under anaerobic conditions. It has applications in various therapeutic conditions such as hypercoagulability, inflammation, impaired perfusion, immuno-modulation, etc.

Funding rounds

• Jul 2025Series B$18.9M
• Jan 2025Series B$20M
• Nov 2024Series B$21.7M
• Dec 2023Series B$5M

Founders & team

Martin CannonFounderAndrew DunhamCEO & CTO

Investors

HHS

Tech stack

Apache Http ServerComplianzCookieyesFont AwesomeGoogle AnalyticsGoogle Font Api

Developer of artificial intelligence to analyze microbial ecosystems for medicine. It builds a closed-loop engine pairing wet lab science with machine learning. This creates foundational models and datasets to advance open science. It enables a new generation of predictive medicine through microbial interactions. The company seeks collaborators with pre/post-intervention datasets of the microbiome.

Funding rounds

• Mar 2026Seed$3.5M

Founders & team

Alex MerwinCo-Founder & COOJenny YangCo-Founder & CEO

Investors

Merantix Capital, Seedcamp, OpenSeed VC, Defined Capital

Tech stack

Framer SitesGodaddyGoogle Font ApiGoogle WorkspaceHstsHttp/3

Pharmaceutical company developing a novel rescue drug for ulcerative colitis flares. Focused on gastroenterology, the company addresses unmet needs in disease management with a low competitive landscape. Their lead product, completing Phase 3 trials, aims for clinical remission with mucosal healing in just four weeks, offering a unique rescue option for ulcerative colitis patients, alone or with maintenance therapies. The company's patented suppository, utilizing a novel hydrocortisone acetate formulation and applicator, ensures consistent drug delivery and eliminates leakage. With a strong IP portfolio extending market exclusivity, they are poised to provide relief from debilitating rectal symptoms and improve the quality of life for those living with ulcerative colitis. This innovative approach solves an unmet need in ulcerative colitis treatment.

Microwave and terahertz systems for nuclear fusion, DNP, NMR, EPR spectroscopy. The company develops high-power microwave, millimeter-wave, and terahertz systems and components. These systems are used for applications like electron cyclotron heating in nuclear fusion reactors, dynamic nuclear polarization enhanced NMR spectroscopy, EPR spectroscopy, material processing, and other scientific and industrial applications. They offer gyrotrons, electron guns, custom vacuum devices, transmission lines, and diagnostic systems. The company focuses on intelligent instruments for accelerating discovery in science and technology, providing solutions for plasma heating and diagnostics, and addressing the terahertz gap with advanced sources and components.

Funding rounds

• Apr 2025Grant (prize money)$199.9K
• Mar 2025Grant (prize money)$2.6M
• Jan 2025Grant (prize money)$1.7M
• Jul 2023Grant (prize money)$400K

Founders & team

Thorsten MalyCo-founder and Vice President Magnetic Resonance

Investors

HHS, OSTI

Tech stack

Amazon CloudfrontAmazon S3Amazon Web ServicesAws Certificate ManagerBootstrapCloudflare

Innovating whole tissue imaging and analysis solutions for life-saving therapies. The company is a life sciences imaging solutions provider, specializing in high-throughput 3D histology and whole tissue studies. They offer services, including study design, imaging, data analysis, and custom assay development. Their technology supports research in areas like Alzheimer's disease, brain mapping, biodistribution, tumor imaging, and liver fibrosis. They utilize platforms to produce high-fidelity multi-color images of whole organs and tissues, enabling quantitative analysis. They provide contract research services, assisting researchers and companies in developing new therapeutics for diseases. Their expertise lies in tissue imaging and analysis, offering both standard and custom data pipelines for processing large data volumes. They work with fixed tissues, providing imaging and processing through standard assays, and also develop custom assays, handling entire studies from tissue labeling through image analysis and final report.